Slovenian society for gastroenterology and hepatology guidelines on the management of Helicobacter pylori infection;Priporočila slovenskega združenja za gastroenterologijo in hepatologijo za zdravljenje okužbe z bakterijo helicobacter pylori

Zdravniski Vestnik

Volumn 80, Issue 9, 2011, Pages 647-656

  Bojan, Tepeš ^a   Borut, Štabuc ^b  

^a Diagnosti ni Center Roga ka   (Slovenia)

^b UKC Ljubljana ^*  (Slovenia)

Author keywords

Antimicrobial resistance; Gastric cancer; Gastritis; Helicobacter pylori; Slovenian society for gastroenterology and hepatology guidelines on the management of hp infection

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYTETRACYCLINE; PROTON PUMP INHIBITOR; SALICYLIC ACID DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; DRUG SUBSTITUTION; DUODENUM ULCER; ERADICATION THERAPY; FECES ANALYSIS; GASTROENTEROLOGY; GENERAL PRACTITIONER; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MEDICAL SOCIETY; MEDICAL SPECIALIST; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PEPTIC ULCER BLEEDING; PRACTICE GUIDELINE; PREVALENCE; RISK FACTOR; SANITATION; SLOVENIA; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH ULCER; TREATMENT DURATION; TREATMENT FAILURE; UREA BREATH TEST;

EID: 82455172099     PISSN: 13180347     EISSN: 15810224     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Marshall BJ. Unidentifed curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1: 1273-4.
2. European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8-13.
3. Malfertheiner P, Megraud F, O'Morain C, Hungin APS, Jones R, Axon A, et al. Current concepts in the management of Helicobacter pylori infection-Te Maastricht 2-2000 Consensus Report. Aliment Phamacol Ter 2002; 16: 167-80.
4. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772- 81.
5. Chey W, Wong B. American College of Gastroen-terology Guideline on the management of Helico-bacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25.
6. Asaka M, Kato M, Takahashi S, Fokuda Y, Sugiya-ma T, Ota H, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 15; 1-20.
7. Tepeš B, Križman I. Priporočila za zdravljenje okužbe z bakterijo Helicobacter pyori v Soveniji. Zdrav Vestn 1998; 67: 159-62.
8. Leodoler A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori -associated gastric or duodenal ulcer. Aliment Pharmacol Ter 2001; 15: 1949-58.
9. Gisbert J P, Khorrami S, Carballo F, Calvet X, Gené E, Dominguez Muñoz JE. H pylori eradication therapy vs.antisecretory non-eradication therapy (with or without long term maintenance antisec-retory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev 2004; (2): CD004062.
10. Tepeš B, Kavčič B, Gubina M, Križman I. A four year follow-up of duodenal ulcer patients afer Helicobacter pylori eradication. Hepatogastroe-nerology 1999; 46: 1746-50.
11. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004; 99: 1833-55.
12. Montalban C, Norman F. Treatment of gastric mu-cosa-associated lymphoid tissue lymphoma: Heli-cobacter pylori etradication and beyond. Expert Rev Anticancer Ter 2006; 6: 361-71.
13. Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Pon-zoni M, Conconi A, et al. Clinical activity of ri-tuximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-He-licobacter pylori therapy. J Clin Oncol 2005; 23: 1979-83.
14. Tepeš B, Kavčič B, Zaletel-Kragelj L, Gubina M, Ihan A, Poljak M. Two-to four-year histologic follow-up of gastric mucosa afer Helicobacter pylori eradication. J Pathol 1999; 188: 24-29.
15. Sung JJ, Lin SR, Ching JY. Atrophy and intestinal metaplasia one year afer cure of H. pylori infection: a prospective randomized study. Gastroente-rology 2000; 119: 7-14.
16. Rocco A, Suriani R, Cardesi E, Venturini I, Maz-zucco D, Nardone G. Gastric atrophy and intestinal metaplasia changes 8 years afer Helicobacter pylori eradication. A blind, randomized study. Minerva Gastroenterol Dietol 2002; 48: 175-8.
17. Ito M, Haruma K. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective studyof patients with atrophic gastritis. Aliment Pharmacol Ter 2002; 16: 1449-56.
18. Zhou L, Sung JJ, Lin S. A fve year follow-up study on the pathologic changes of gastric mucosa afer Helicobacter pylori eradication. Chin Med J 2003; 116: 11-14.
19. Lu B, Chen MT, Fan YH, Liu Y, Meng LN. Efects of Helicobacter pylori eradication on atrophic gastritis and intestinal metaplasia: a 3-year follow-up study. Word J Gastroenterol 2005; 11: 6518-20.
20. Salih BA, Abasiyanik MF, Saribasak H, Huten O, Sander E. A folloow-up study on the efect of He-licobacter pylori eradication on the severity of gastric histology. Dig Dis Sci 2005; 50: 1517-22.
21. Mera R, Fontham ET, Bravo LE. Long term fo-loww-up of patients treated for Helicobacter pylori infection. Gut 2005; 54: 1536-40.
22. Arkkila PE, Seppala K, Farkkila M, Veijola L, Si-pponen P. Helicobacter pylori eradication in the healing of atrophic gastritis: one year prospective study. Scand J Gastroenterol 2006; 41: 782-90.
23. Correa P, Fontham ET, Bravo JC. Chemopreven-tion of gastric dysplasia: randomized trial of anti-oxidant supplements and anti Helicobacter pylori therapy. J Natl Cancer Inst 2000; 92: 1881-8.
24. You WC, Brown LM, Zhang L. Randomized double blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006, 98: 974-83.
25. IARC Working Group on the evaluation of Carcinogenic Risks to Humans. Helicobacter pylori. In: Schistosomes, Liver Flukes and Helicobacter pylori. Views and expert Opinions of an IARC Working Group on the Evaluation of carcinogenic Risks to Humans. Lyon: IARC; 1994. p. 177-240.
26. Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cad-herin) mutation carriers from hereditary difuse gastric cancer families. Gastroenterology 2001; 12: 1348-53.
27. Caldas C, Carneiro F, Lynch HT, Yokota J, Wie-sner GL, Powell SM, et al. Familial gastric cancer: overview and guidelines for management. J Med Genet 1999; 36: 873-80.
28. Norton JA, Ham CM, Dam JV, Jefrey RB, Longac-re TA, Huntsman DG, et al. CDH1 truncating mutations in the E-Cadherin gene: in indication for total gastrectomy to treat hereditary difuse gastric cancer. Ann Surg 2007; 245: 873-879.
29. El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, et al. Increased risk of noncardia gastric cancer associated with pro-infammatory cytokine gene polimorphisms. Ga-stroenterology 2003; 124: 1193-1201.
30. Figueireido C, Machado JC, Pharoah PP, Seruca R, Sousa S, Carvalho R, et al. Helicobacter pylori and interleukin 1 genotyping; an oppurtunity to identify high risk individuals for gastric carcinoma. J Natl Cancer Inst 2002; 94: 1680-7.
31. Hold GL, Rabkin CS, Chow WH. A functional polymorphisms of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007; 132: 905-12.
32. Wang C, Yuan Y, Hunt RH. Te association between Helicobacter pylori and early gastric cancer: a meta analysis. Am J Gastroenterol 2007; 102: 1789-98.
33. Brenner H, Arndt V, Stagmaier C, Ziegler H, Rothenbacher D. Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol 2004; 159: 252-58.
34. Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, et al. Efect of Helicobac-ter pylori eradication on subsequent development of cancer afer endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 639-42.
35. Wong BC, Lam SK, Wong WM. Helicobacter pylori eradication to prevent gastric cancer in high risk region of China: a randomized control trial. JAMA: 2004; 291: 187-94.
36. Fukase K, Kato M, Kokuchi S, Inoue K, Uemura N, Okamoto S, et al. Efect of eradication of He-licobacter pylori on incidence of metachronous gastric carcinoma afer endoscopic resection of early gastric cancer: an open-labeled, randomised control trial. Lancet 2008; 372: 350-2.
37. Spiegel BM, Vakil NB, Ofmann JJ. Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology 2002; 122: 1270-85
38. Moayyedi P, Deeks J, Talley NJ, Delaney B, For-man D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003; 98: 2621-6.
39. Lanas A, Garcia-Rodriguez LA, Arroyo MT, Bu-janda L, Gomoll F, Montserrat F, et al. Efect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-in-fammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007; 102: 507-515.
40. Du Bois S, Kearney D. Iron-defciency anemia and Helicobacter pylori infection. A review of evidence. Am J Gastroenterol 2005; 100: 453-9.
41. Baggett HC, Parkinson AJ, Muth PT, Gold BD, Gessner BD. Endemic iron defciency associated with Helicobacter pylori infection among school-aged children in Alaska. Pediatrics 2006; 117: 396-404.
42. Franchini M, Cruciani MM, Mengoli CC. Efect of Helicobacter pylori eradication on platel count in idiopatic trombocitopenic purpura: a systematic review and meta analysis. J Antimicrob Chemoter 2007; 60: 237-46.
43. Federman DG, Kirsner RS, Moriarty JP, Concato J. Te efect of antibiotic therapy for patients infected with Helicobacter pylori who have chronic urticaria. J Am Acta Dermatol 2003; 49: 861-4.
44. Fukuda S, Shimoyama T, Umegaki N, Mikami T, Nakano H, Munakata A. Efect of Helicobacter pylori eradication in the treatment of Japanese patients with chronic idiopatic urticaria. J Gastroen-terol 2004; 39: 827-30.
45. McColl KE, Dickson A, El-Nujumi A, El-Omar E, Kelman A. Simptomatic beneft 1-3 years afer H pylori eradication in ulcer patients: impact on ga-stroesophageal refux disease. Am J Gastroenterol 2000; 95: 101-5.
46. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate refux symptoms in gastro-esophageal refux disease. Gastroenterology 2001; 121: 1120-6.
47. Laine S, Sugg J. Efect of Helicobacter pylory era-dication on development of erosive esophagitis and gastroesophageal refux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002; 97: 1992-7.
48. Schenk BE, Kujpers EJ, Nelis GF, Bloemena E, Tijs JC, Snel P, et al. Efect of Helicobacter pylori eradication on chronic gastritis during omeprazo-le therapy. Gut 2000; 46: 615-21.
49. Kujpers EJ, Nelis GF, Klinkenberg Knol EC, Snel P, Goldfain D, et al. Cure of Helicobacter pylori infection in patients with refux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation ofrefux disease: results of randomized controlled trial. Gut 2004; 53: 12-20.
50. Tepeš B. Diagnostika okužbe z bakterijo Helico-bacter pylori. Farm vestn 1998; 49353-61.
51. Tepeš B. Helicobacter pylori v novem milenijumu. Gastroenterolog 2004; 8 (supl 2): 54-9.
52. Tepeš B. Comparison of two invasive diagnostic tests for Helicobacter pylori afer antimicrobial therapy Scand J Gastroenterol 2007; 42: 330-32.
53. Bochenek VJ, Peters S, Fraga PD. Helicobacter pylori pantoprazole eradication (HELPPE) study group. Eradication of Helicobacter pylori by 7-day triple regiments combining pantoprazole with clarithromycin, metronidazole, or amoksicillin in patients with peptic ulcer disease: results of two double-blind,randomized studies. Helicobacter 2003, 8: 626-42.
54. Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ter 2004; 20: 99-107.
55. Tepeš B, Ojsteršek Z. Uspešnost zdravljenja okuž-be s Helicobacter pylori v Sloveniji v letu 2008. Zdrav Vestn 2010; 79: 19-24.
56. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007; 133: 996-1001.
57. Gubina M, Tepeš B, Gorenšek M, Križman I, Ihan A, Poljak M. Sensitivity of Helicobacter pylori to eight antibiotics. Te 5 th International conference of the Macrolides, Azolides, Streptogromines and ketolides; 2000 Jan 26-28; Seville, Spain. p. 86.
58. Jeverica S, Tepeš B, Ihan A, Škvarč M. Primarna odpornost bakterije Helicobacter pylori. Zdrav Vestn 2010; 79: 25-30.
59. Megraud F, Burette A, Glupczynski Y, Fiocca R, Logan R, Quina M, Comparison of tests for assessment of Helicobacter pylori eradication: results of a multi-center study using centralized facility testing. Eur J Gastroenterol Hepatol 2000; 12: 629-33.
60. Vaira D, Malfertheiner P, Megraud F, Axon AT, Deltenre M, Gasbarrini G. Noninvasive antigen based assay for assessing Helicobacter pylori eradication: a European multicenter study. the European Helicobacter pylori HpSA Study Group. Am J Gastroenterol 2000, 95: 925-9.
61. Tepeš B, Gubina M. Razlogi za neuspeh antimi-krobnega zdravljenja okužbe z bakterijo Helico-bacter pylori in naše terapevtske možnosti. Zdrav Vestn 2004; 73: 5003-6.
62. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efcacy of the second-line treatment regiments for Helicobacter pylori infection. Scand J Gastroenterol 2001; 36: 690-700.
63. Gisbert JP, Calvet X, O'Connor JPA, Megraud F, O'Morain CA. Te sequential therapy regimen for Helicobacter pylori eradication. Expert Opin Pharmacoter 2010; 11: 905-18.
64. Jafri NS, Hornung CA, Howden C W. Meta--analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naïve to treatment. Ann Intern Med 2008; 148: 923-31.
65. Gisbert JP. Morena F. Systematic review and meta analysis: levofoksacine-based rescue regiments afer Helicobacter pylori treatment failure. Aliment Pharmacol Ter 2006; 23: 35-44.
66. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000, the global picture. Eur J Cancer 2001; 37: S4-66.
67. Rakv Sloveniji 2007. Ljubljana: Onkološki inštitut Ljubljana; 2010.
68. Tepeš B. Can gastric cancer be prevented? J Physi-ol Pharmacol 2009; 60 (Suppl 7): 71-7.
69. Talley NJ, Fock KM, Moayyedi P. Gastric cancer consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high risk populations to prevent gastric cancer. Am J Gastroenterol 2008; 103: 510-14.
70. Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-efectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996; 348: 150-4.
71. Fendrick AM, Chernew ME, Hirth RA, Bloom BS, Bandekar RR, Scheiman JM. Clinical and economic efects of population - based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med 1999; 159: 142-8.
72. Gubina M, Tepeš B, Vidmar G, Ihan A, Logar J, Wraber-Herzog B. Prevalenca protiteles proti bak-teriji Helicobacter pylori v Sloveniji v letu 2005. Zdrav Vestn 2006; 75: 169-73.